Form 4: Avalo Therapeutics Director Granted 20,100 Stock Options
Director Equity Grant
Avalo Therapeutics, Inc. Director June Sherie Almenoff was granted 20,100 stock options with an exercise price of $4.47, vesting fully on the first anniversary of the grant date.
Summary
- June Sherie Almenoff, a Director of Avalo Therapeutics, Inc. (AVTX), was granted 20,100 stock options.
- The stock options have an exercise price of $4.47 per share.
- The grant date for these options was June 17, 2025.
- The options vest 100% on the first anniversary of the grant date, contingent on her continued service.
- The expiration date for these options is June 17, 2035.
Sentiment
Score: 6
Explanation: The filing reports a standard equity grant to a director, which is a neutral to slightly positive event as it aligns the director's interests with shareholders. It does not contain any negative news or significant positive operational updates.
Positives
- The grant of 20,100 stock options to Director June Sherie Almenoff aligns her interests with those of shareholders, incentivizing long-term company performance.
Negatives
- NA
Risks
- NA
Future Outlook
The stock options granted to Director June Sherie Almenoff are scheduled to vest 100% on the first anniversary of the grant date, June 17, 2025, subject to her continued service.
Management Comments
- NA
Industry Context
The granting of stock options to directors is a common practice in the biotechnology and pharmaceutical industry, aligning executive incentives with long-term shareholder value creation. This type of equity compensation is a standard component of director remuneration packages, particularly for companies like Avalo Therapeutics, Inc., which are often in growth or development phases.
Comparison to Industry Standards
- NA
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
Legal Proceedings
- NA
Related Party Transactions
- NA
Stakeholder Impact
- Shareholders: The grant of stock options to a director helps align the director's long-term interests with those of the shareholders, potentially leading to better governance and strategic decisions aimed at increasing share value.
Next Steps
- The stock options will vest 100% on the first anniversary of the grant date (June 17, 2026), subject to the director's continued service.
Key Dates
| Date | Description |
|---|---|
| 06/17/2025 | Date of stock option grant and earliest transaction date. |
| 06/18/2025 | Date the Form 4 was signed. |
| 06/17/2026 | Approximate vesting date for the stock options (first anniversary of grant date). |
| 06/17/2035 | Expiration date of the stock options. |
Keywords
Avalo Therapeutics, AVTX, Stock Options, Director Compensation, SEC Form 4, Beneficial Ownership, Equity Grant
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.